Rockefeller University-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013583)
◆英語タイトル:Rockefeller University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013583
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Rockefeller University (Rockefeller) is a biomedical research university that provides graduate and postdoctoral educational programs. The university offers various educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies in the areas of addictive diseases, auditory studies, blood disorders, cancer, immunology, neurologic and psychiatric disorders, and others. Rockefeller offers research services in chemical and structural biology, genetics and genomics, molecular and cell biology, neurosciences and behavior, immunology, virology and microbiology, medical sciences, systems physiology and human genetics, organismal biology, evolution, ethology and ecology, physical, mathematical and computational biology, stem cells, development, and regeneration and aging. The university provides professional and financial support services. Rockefeller is headquartered in New York, the US.

Rockefeller University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockefeller University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rockefeller University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rockefeller University, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ContraFect Enters into Research Agreement with Rockefeller University 11
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 12
QR Pharma Enters into Research Agreement with Rockefeller University 13
Licensing Agreements 14
Frontier Biotechnologies Enters into Licensing Agreement with Rockefeller University 14
Cerevance Enters into Licensing Agreement with Rockefeller University 15
ContraFect Enters into Licensing Agreement with Rockefeller University for lysine CF-301 16
ContraFect Enters Into Licensing Agreement With Rockefeller University 17
Lodo Therapeutics Enters into Licensing Agreement with Rockefeller University 18
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 19
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 21
Rockefeller University – Key Competitors 22
Rockefeller University – Key Employees 23
Rockefeller University – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 24
Recent Developments 25
Strategy And Business Planning 25
Oct 31, 2016: Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept 25
Government and Public Interest 27
Nov 02, 2017: Potential new treatment for Fragile X targets one gene to affect many 27
Jul 24, 2017: Researchers develop new method to generate human antibodies 28
Jun 09, 2017: NIH Funds NYC Center for AIDS Research 29
Mar 06, 2017: A new way to reset gene expression in cancer cells shows promise for leukemia treatment 30
Feb 24, 2017: New structural studies reveal workings of a molecular pump that ejects cancer drugs 32
Feb 03, 2017: Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs 33
Dec 06, 2016: Researchers discover a new gatekeeper controlling T cell release into the bloodstream 34
Nov 23, 2016: Study shows low-dose chemotherapy regimens could prevent tumor recurrence in some cancers 35
Sep 29, 2016: Rockefeller University awarded $27 million NIH grant to fund clinical and translational science in Hospital 36
Sep 22, 2016: A compound that stops cells from making protein factories could lead to new antifungal drugs 37
Jul 13, 2016: The Wistar Institute and Partners Receive Nearly $23 Million from NIH to Advance HIV Cure Research 38
May 30, 2016: A combined approach to treating metastatic melanoma 39
Apr 25, 2016: Fisher Center Scientists Discover Pathway That may Lead to Alzheimer’s Disease 40
Mar 01, 2016: New research clarifies how stem cells get activated to produce new hair—and what happens when their regenerative powers wear out 41
Feb 03, 2016: Study reveals how herpes virus tricks the immune system 42
Jan 14, 2016: Signals that make early stem cells identified 43
Product News 45
05/05/2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs 45
02/06/2017: Encouraging clinical results for an antibody drug to prevent or treat HIV 46
01/17/2017: Successful antibody trial in HIV-infected individuals 47
Clinical Trials 48
May 06, 2016: Antibody therapy opens door to potential new treatment for HIV 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Rockefeller University, Pharmaceuticals & Healthcare, Key Facts 2
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockefeller University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockefeller University, Deals By Therapy Area, 2011 to YTD 2017 9
Rockefeller University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ContraFect Enters into Research Agreement with Rockefeller University 11
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 12
QR Pharma Enters into Research Agreement with Rockefeller University 13
Frontier Biotechnologies Enters into Licensing Agreement with Rockefeller University 14
Cerevance Enters into Licensing Agreement with Rockefeller University 15
ContraFect Enters into Licensing Agreement with Rockefeller University for lysine CF-301 16
ContraFect Enters Into Licensing Agreement With Rockefeller University 17
Lodo Therapeutics Enters into Licensing Agreement with Rockefeller University 18
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 19
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 21
Rockefeller University, Key Competitors 22
Rockefeller University, Key Employees 23
Rockefeller University, Joint Venture 24

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Rockefeller University-製薬・医療分野:企業M&A・提携分析(Rockefeller University - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆